Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus QBREXZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus QBREXZA.
DICYCLOMINE HYDROCHLORIDE vs QBREXZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
10-20 mg orally 3-4 times daily
1 capsule (40 mg) orally twice daily with or without food.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination.
Category A/B
Category C
Anticholinergic
Anticholinergic